Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable

  • Technology appraisal guidance
  • TA1048
  • Published: 
Following information received from the company the timelines for this appraisal are currently to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.